For the quarter ending 2025-09-30, CI had $1,685M increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net income | 1,973 | 1,632 | 1,409 | 1,536 |
| Depreciation and amortization | 697 | 682 | 674 | 646 |
| Investment (gains) losses, net | 26 | 52 | -2 | -2,737 |
| Deferred income tax benefit | -118 | 76 | 216 | -256 |
| (gain) loss on sale of businesses | 38 | 0 | 41 | 130 |
| Accounts receivable, net | 513 | 4,193 | 2,205 | -3,231 |
| Inventories | -334 | 791 | -1,517 | 1,609 |
| Reinsurance recoverable and other assets | 135 | 183 | 219 | 127 |
| Insurance liabilities | -40 | -76 | 1,778 | -377 |
| Pharmacy and other service costs payable | 842 | 860 | 135 | -222 |
| Accounts payable and accrued expenses and other liabilities | 163 | 154 | -1,174 | 1,957 |
| Other, net | -43 | -157 | -260 | -119 |
| Net cash provided by operating activities | 3,418 | -1,886 | 1,920 | 5,212 |
| Debt securities and equity securities | 246 | 178 | 94 | 287 |
| Debt securities and equity securities | 192 | 331 | 222 | 254 |
| Commercial mortgage loans | 108 | 5 | 85 | 109 |
| Other sales, maturities and repayments (primarily short-term and other long-term investments) | 225 | 100 | 331 | 185 |
| Debt securities and equity securities | 3,759 | 560 | 952 | 443 |
| Commercial mortgage loans | 55 | 28 | 34 | 0 |
| Other (primarily short-term and other long-term investments) | 305 | 286 | 475 | 281 |
| Property and equipment purchases, net | 278 | 285 | 327 | 337 |
| Acquisitions, net of cash acquired | 597 | - | - | -1 |
| Divestitures, net of cash sold | 0 | 0 | 2,346 | 521 |
| Renewable energy tax credit equity investments | 158 | 235 | 92 | 1,030 |
| Other, net | 6 | 17 | 1 | -543 |
| Net cash used in investing activities | -4,387 | -797 | 1,197 | -191 |
| Deposits and interest credited to contractholder deposit funds | 39 | 38 | 36 | 46 |
| Withdrawals and benefit payments from contractholder deposit funds | 64 | 73 | 64 | 48 |
| Net change in short-term debt, excluding term loan | -1,211 | 1,187 | -891 | -768 |
| Net proceeds on issuance of term loan | 1,999 | - | - | - |
| Repayment of term loan | 2,000 | - | - | - |
| Repayment of long-term debt | 43 | 900 | 700 | 0 |
| Net proceeds on issuance of long-term debt | 4,461 | 0 | 0 | 0 |
| Repurchase of common stock | 0 | 1,112 | 1,508 | 2,022 |
| Issuance of common stock | 37 | 72 | 69 | 22 |
| Common stock dividend paid | 402 | 401 | 412 | 384 |
| Other, net | -157 | -144 | -211 | -94 |
| Net cash used in financing activities | 2,659 | -1,333 | -3,681 | -3,248 |
| Effect of foreign currency rate changes on cash, cash equivalents and restricted cash | -5 | 26 | 9 | -26 |
| Net decrease in cash, cash equivalents and restricted cash | 1,685 | -3,990 | -555 | 1,747 |
| Cash and cash equivalents at beginning of period | 4,386 | 8,376 | 8,931 | 7,184 |
| Cash and cash equivalents at end of period | 6,071 | 4,386 | 8,376 | 8,931 |
Cigna Group (CI)
Cigna Group (CI)